• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Alpine Immune Sciences, Inc.

    < Previous 1 2 Next >
    Alpine Immune Sciences Reports First Quarter 2024 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN VRTX
    Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Proposed Public Offering
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    Alpine Immune Sciences Reports First Quarter 2023 Financial Results
    From Alpine Immune Sciences, Inc.
    Via Business Wire
    Tickers ALPN
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.